Showing posts with label implementation of research findings. Show all posts
Showing posts with label implementation of research findings. Show all posts

Wednesday, September 17, 2014

The Myth of "Cross-Addiction" Debunked

For decades, the conventional wisdom and clinical lore in rehab facilities and recovery communities has warned against the risks of so-called "cross-addiction". "Be careful," they say, "you're at-risk of picking up a new addiction now that you've kicked one habit." Heroin addicts are warned against developing an addiction to alcohol, and cocaine addicts are warned against developing an addiction to opiates, Cross-addiction can even occur to things like exercise or sugar, according to pamphlets and even therapists who have worked in the field for years and years.

But is it even true? Is the notion of cross-addiction supported by empirical evidence - or does it fall on its face under scientific scrutiny?

According to a new report, published September 10 in JAMA Psychiatry, the answer is a resounding, "No."

The study, "Testing the Drug Substitution Switching-Addictions Hypothesis," analyzed data from the National Epidemiological Study on Alcohol and Related Conditions (NESARC) to investigate whether participants developed new-onset substance use disorders (SUD) after remission from a previous SUD. These data were then compared against people with a SUD who did not achieve remission but also developed a new-onset SUD.

The authors discovered that, "As compared with those who do not remit from an SUD, remitters have less than half the risk of developing a new SUD. Contrary to clinical lore, achieving remission does not typically lead to drug substitution but rather is associated with a lower risk of new SUD onsets."

This is probably the best evidence to-date that addresses the concept of cross-addiction. Will counselors and agencies begin to pull back from this concept - or will clients still be subjected to homework assignments and lectures warning against it?

Here's the abstract from JAMA Psychiatry (found here: http://archpsyc.jamanetwork.com/article.aspx?articleid=1901525):

Importance  Adults who remit from a substance use disorder (SUD) are often thought to be at increased risk for developing another SUD. A greater understanding of the prevalence and risk factors for drug substitution would inform clinical monitoring and management.
Objective  To determine whether remission from an SUD increases the risk of onset of a new SUD after a 3-year follow-up compared with lack of remission from an SUD and whether sociodemographic characteristics and psychiatric disorders, including personality disorders, independently predict a new-onset SUD.
Design, Setting, and Participants  A prospective cohort study where data were drawn from a nationally representative sample of 34 653 adults from the National Epidemiologic Survey on Alcohol and Related Conditions. Participants were interviewed twice, 3 years apart (wave 1, 2001–2002; wave 2, 2004–2005).
Main Outcomes and Measures  We compared new-onset SUDs among individuals with at least 1 current SUD at wave 1 who did not remit from any SUDs at wave 2 (n = 3275) and among individuals with at least 1 current SUD at wave 1 who remitted at wave 2 (n = 2741).
Results  Approximately one-fifth (n = 2741) of the total sample had developed a new-onset SUD at the wave 2 assessment. Individuals who remitted from 1 SUD during this period were significantly less likely than those who did not remit to develop a new SUD (13.1% vs 27.2%, P < .001). Results were robust to sample specification. An exception was that remission from a drug use disorder increased the odds of a new SUD (odds ratio [OR] = 1.46; 95% CI, 1.11-1.92). However, after adjusting for the number of SUDs at baseline, remission from drug use disorders decreased the odds of a new-onset SUD (OR = 0.66; 95% CI, 0.46-0.95) whereas the number of baseline SUDs increased those odds (OR=1.68; 95% CI, 1.43-1.98). Being male, younger in age, never married, having an earlier age at substance use onset, and psychiatric comorbidity significantly increased the odds of a new-onset SUD during the follow-up period.
Conclusions and Relevance  As compared with those who do not remit from an SUD, remitters have less than half the risk of developing a new SUD. Contrary to clinical lore, achieving remission does not typically lead to drug substitution but rather is associated with a lower risk of new SUD onsets.

Friday, March 21, 2014

What Aren't More Docs Prescribing Buprenorphine?

On the heels of recent coverage over the "dangers" of the medication buprenorphine, researchers are seeking to better understand what keeps doctors from using one of the two the most effective tools for opioid use disorders at their disposal. The most recent study, "Barriers to Primary Care Physicians Prescribing Buprenorphine", was published in the Annals of Family Medicine and is available in-full online - for free. The study came out of the Rural Opioid Addiction Management in Washington state, during which 120 physicians were trained in opioid addiction and buprenorphine prescribing. Disappointingly, of the 78 respondents who were analyzed for the study, 50 went on to obtain a DATA waiver, yet a mere 22 doctors ever went on to prescribe the medication to anyone. It begs the question: why aren't more docs prescribing buprenorphine?

Here's the breakdown from the piece of perceived barriers to prescribing:























Among the barriers cited by the doctors in the study, "Lack of psychosocial support" was cited as the number one barrier by both prescribers and non-prescribers, despite the lack of evidence that behavioral adjuncts or additional counseling improve outcomes. (Granted, the authors point out that in order to get reimbursed by a number of payers, additional counseling must be offered to patients.)

A quick scan across the literature leads us to another important and common driver of physician attitudes toward this medication: institutional support. It appears that study after study cite the impact of the hospital/clinic/practice culture on the subsequent interest. training and prescription of buprenorphine by its docs. In the present study, "resistance from practice partners" and "lack of institutional support" were commonly cited as barriers. A recent article from the March issue of the Journal of Substance Abuse Treatment described how important "A strong leader championing the new treatment" was to the implementation of buprenorphine prescribing across a large system. 

What do you think? How can we be more effective at impacting change at the prescriber level? If culture plays an important role, how do we improve the culture around this proven tool?

Thursday, March 6, 2014

"First Controlled Study of LSD-Assisted Psychotherapy in More Than 40 Years"

Researchers from Switzerland and the Multidisciplinary Association for Psychedelic Studies have conducted what they are calling the first study of its kind in over 40 years: a randomized, double-blind, active placebo-controlled study of LSD-assisted psychotherapy. The participants, 12 patients with anxiety related to life-threatening illnesses like metastatic cancer, non-Hodgkin's lymphoma, Parkinson's disease, etc., participated in drug-free therapy sessions as well as 2 LSD-assisted psychotherapy sessions over the course of the study. Follow-up interviews were conducted at 2- and 12-months post-treatment and indicated lasting, statistically-significant improvements in anxiety. The study is posted in its entirety for free online via The Journal of Nervous and Mental Disease.

The main outcome measures were scores on the State-Trait Anxiety Inventory (STAI). Exclusion criteria included current drug or alcohol disorders, primary psychotic, dissociative or bipolar 1 disorders, neurocognitive impairment or pregnancy/nursing. Participants in the experimental arm participated in 2 full-day LSD-assisted psychotherapy sessions, 2 to 3 weeks apart, that were "embedded within an ongoing process of [six]drug-free psychotherapy sessions for preparatory and integrative purposes." Subjects received doses of 200 micrograms of pure LSD and the day-long sessions lasted 8 hours, or until the effects of the medication wore off. Participants in the active placebo group received the exact same set of psychotherapy sessions, but were given 20-microgram doses of LSD. After the 2-month follow-up interview, these participants were informed of their place in the control group and were offered the full, open-label intervention.

The results indicate statistically significant STAI scores for both state and trait anxiety at 2 and 12 months for the experimental groups. The active placebo did not produce statistically-significant improvements. The researchers calculate the effect size at 1.1 for trait anxiety, and 1.2 for state anxiety. They also, as you would imagine, call for more research with larger controlled studies. Importantly, neither the experimental drug nor the placebo produced any serious adverse effects, leading the authors to seem confident in the safety of this type of therapy.

Considering the research on LSD ground to a halt by the 1970s, do readers think it's time to revisit this(or other psychedelics, for that matter) as a therapeutic tool? If you have experience with this, it would be fascinating to hear your take, too.

Interested to hear readers opinions on the matter...

Source:
http://journals.lww.com/jonmd/Documents/90000000.0-00001.pdf

Wednesday, February 19, 2014

Computerized Vs In-Person Brief Intervention for Drug Misuse: RCT

We have written much about the challenges of widespread implementation of SBIRT in the US. Well, authors of a new study, published online this month in the journal, Addiction, have suggested a novel tool which they believe could help ensure that scores of additional patients are being screened: computerized brief intervention. And according to their study, it works as well and the in-person version:

Abstract

Background and aims

Several studies have found that brief interventions (BIs) for drug misuse have superior effectiveness to no-treatment controls. However, many health centers do not provide BIs for drug use consistently due to insufficient behavioral health staff capacity. Computerized BIs for drug use are a promising approach, but their effectiveness compared with in-person BIs has not been established. This study compared the effectiveness of a computerized brief intervention (CBI) to an in-person brief intervention (IBI) delivered by a behavioral health counselor.

Methods

Two-arm randomized clinical trial, conducted in two health centers in New Mexico, USA. Participants were 360 adult primary care patients with moderate-risk drug scores on the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) who were randomly assigned on a 1:1 basis to a computerized brief intervention (CBI) or to an in-person brief intervention (IBI) delivered by a behavioral health counselor. Assessments were conducted at baseline and 3-month follow-up, and included the ASSIST and drug testing on hair samples.

Results

The IBI and CBI conditions did not differ at 3 months on global ASSIST drug scores (b=-1.79; 95% CI=-4.37,-0.80) or drug-positive hair tests (OR=.97; 95% CI= 0.47,1.94). There was a statistically significant advantage of CBI over IBI in substance-specific ASSIST scores for marijuana (b=-1.73; 95% CI= -2.91,-0.55; Cohen's d=.26; p=.004) and cocaine (b= -4.48; 95% CI= -8.26,-0.71; Cohen's d=.50; p=.037) at 3 months.

Conclusions

Computerized brief intervention can be an effective alternative to in-person brief intervention for addressing moderate drug use in primary care.

What do you think - could computerized brief interventions be the key to widespread SBIRT implementation?

Source: http://onlinelibrary.wiley.com/doi/10.1111/add.12502/abstract 

Thursday, February 13, 2014

Gaps in Clinical Prevention and Treatment for Alcohol Use Disorders


Dr W's article, "Gaps in Clinical Prevention and Treatment for Alcohol Use Disorders" was published this month online in the journal Alcohol Research: Current Reviews. Here's the abstract:

Abstract

Heavy drinking causes significant morbidity, premature mortality, and other social and economic burdens on society, prompting numerous prevention and treatment efforts to avoid or ameliorate the prevalence of heavy drinking and its consequences. However, the impact on public health of current selective (i.e., clinical) prevention and treatment strategies is unclear. Screening and brief counseling for at-risk drinkers in ambulatory primary care has the strongest evidence for efficacy, and some evidence indicates this approach is cost-effective and reduces excess morbidity and dysfunction. Widespread implementation of screening and brief counseling of nondependent heavy drinkers outside of the medical context has the potential to have a large public health impact. For people with functional dependence, no appropriate treatment and prevention approaches currently exist, although such strategies might be able to prevent or reduce the morbidity and other harmful consequences associated with the condition before its eventual natural resolution. For people with alcohol use disorders, particularly severe and recurrent dependence, treatment studies have shown improvement in the short term. However, there is no compelling evidence that treatment of alcohol use disorders has resulted in reductions in overall disease burden. More research is needed on ways to address functional alcohol dependence as well as severe and recurrent alcohol dependence.

And check out the full piece here:

Wednesday, January 8, 2014

Wacky Progressives and Scientific Illiteracy

In a disturbing article in the New York Times, Amy Harmon chronicles the tale of a brave county councilman on the island of Kona, Hawaii, who refused to be steamrolled by those who categorically believe that genetically modified organisms (GMOs) are dangerous and should be banned across the board. He actually took the time to look into the scientific research, to consult with scientists who know about this, and he attempted to draw a reasonable conclusion. He is faced, however, with a group of true believers, who keep repeating obscure claims based on long-discredited "research." They shout down their opponents and make outlandish claims that have no scientific basis or rationale. They demonize their opponents, and constantly shift the arguments when faced with scientific facts. Most disturbing of all was the refusal of his fellow council members to even allow scientists to testify, instead giving the floor repeatedly to unqualified zealots who continued to make broad, unsupportable statements. 

It turns out, then, that it's not only climate-change deniers and birthers who maintain passionately held beliefs that have no scientific basis. Worse, it shows how repeating false claims becomes a sort of echo chamber for those with similar beliefs. Finally it shows that such behavior is not limited to Tea Party fanatics or religious zealots, but applies equally to so-called progressives on the left side of the political spectrum. I write about this because it applies as well to too much in the fields of psychotherapy, behavior change and addiction treatment.

We tolerate too much of this type of thinking in our field. How many treatment centers offer "holistic" therapies such as yoga, energy field work, Reiki, or massage, or worse, "nutritional treatment" that is not only unsupported, but may well be harmful? Why are state agencies still allowing such centers to obtain licensure? Why are people paying for brain scans or quantitative EEGs or neurofeedback? And, of course, why do so many people cling to the fiction that 90x90 is effective for most people, or that 12-step approaches are 100% effective if you follow directions? (What treatments for human maladies, short of penicillin for strep throat, can claim 100% effectiveness?)

I'm not arguing that an absence of evidence of effectiveness is evidence of ineffectiveness. There is lots we all do that hasn't been studied well, simply because it is impossible to conduct a large randomized controlled trial on every possible therapy. However, in addiction treatment we have a very large and very strong evidence base from which to draw. It's actually far better than in many other areas of health care. In order to include an approach in a licensed program, at the least, we should require 1) a scientifically plausible rationale for a treatment, 2) that unsupported treatments should not be likely to cause significant harm or cost a significant amount of money, 3) that there is not significant evidence that the approach is not effective, and 4) that there is not a well-supported approach already available.

I'm also not suggesting that yoga, meditation, Reiki, energy field work, reflexology, acupuncture, massage, etc., may not be experienced as beneficial to some people. I recently underwent Rolfing, for example, which I found to be very helpful (if painful). But I didn't expect my health insurance to pay for it, and I reject any large claims concerning what it and similar approaches might accomplish. Such approaches might be made available to clients (at their own expense), but not as presented as a scientifically based health practice.

I have been surprised at how trendy the psychotherapy community is in general, not just in addiction treatment. One current example is the spread of dialectical behavior therapy (DBT) beyond its proven focus on borderline personality disorder. It seems that it's being applied to anyone and for every condition short of psychosis. Another trend is "trauma informed therapy" using eye-movement desensitization and reprocessing therapy (EMDR), DBT, prolonged exposure, or mindfulness. All of a sudden, everyone has "trauma" for which these are appropriate treatments, even though many do not meet criteria for post-traumatic stress disorder (PTSD.) What was psychoanalysis if not focused on trauma? For that matter, "mindfulness" is another trendy approach, with practitioners charging for something the Buddha gave away 2600 years ago and which can be had for free at your local Buddhist meditation center.

At the same time, I seldom encounter high quality cognitive-behavior therapy (CBT) being applied to co-existing anxiety or depressive disorders, in spite of a mountain of evidence supporting their effectiveness. And too many in our field still believe that "I don't believe in it" is an adequate reason to not support anti-relapse medications that also have a strong evidence base. When we have such well-supported therapies, why aren't we using them? Why are we instead embracing half-baked ideas and approaches? Why do we tolerate so much scientific ignorance? Why do we tolerate lack of informed consent, where clients are not given information about what the evidence supports and what it does not, but instead receive biased and incorrect information that deprives them of the opportunity to make an informed decision?

Monday, November 25, 2013

12-Step Familiarity vs 12-Step Facilitation

A pair of studies were published last month to little fanfare and which seem to be contradictory in nature. Both papers involve 12-step programs and focus on the role of the counselor in delivering Twelve-Step Facilitation (TSF), a SAMHSA-recognized evidence-based practice. Published in the American Journal of Drug and Alcohol Abuse, the studies come to the following conclusions: Therapist familiarity and personal experience with twelve-step programs (TSPs) improves their credibility among clients and, in turn, therapeutic alliance; yet therapists who viewed TSPs favorably and who described themselves as being in recovery tended to do a poorer job at maintaining fidelity and adherence to TSF in a large, multi-site trial.

In the first paper, researchers at the State University of New York administered surveys to clients and counselors at a host of treatment programs in and around Albany. Clients (n=180) rated counselors on their perceived familiarity with  TSPs, the amount of time in-session devoted to discussion of TSPs, and the credibility of each counselor, as rated in a 12-point questionnaire. In addition, counselors (n=30) answered a demographic questionnaire, reporting such information as education level, recovery status, and months of experience in the field. As hypothesized, counselors who were perceived to be in recovery and more personally-familiar with TSPs received higher ratings of credibility from their clients, presumably resulting in better therapeutic alliances and, therefore, better outcomes.

In the second paper, researchers in Oregon and California sought to determine the characteristics associated with fidelity and TSF adherence among therapists participating in a large trial of the EBP. Notably, the authors found that 1) "Therapists reporting more positive attitudes toward 12-step groups had lower adherence ratings;" 2) "Being in recovery was associated with lower fidelity in univariate tests, but higher adherence in multivariate analysis;" and 3), "Fidelity was higher for therapists reporting self-efficacy in basic counseling skills" (as well as for therapists with a graduate degree) "and lower for self-efficacy in addiction-specific counseling skills." 

The "juxtaposition" of the two outcomes, as Yale's Steve Martino puts it, leads the reader to believe that the ideal therapist in this setting can't possibly exist, or ar the very least is exceedingly rare. Someone who is very familiar with 12-step principles is likely to report a positive attitude toward them, and counselors in recovery are likely to rate themselves as possessing strong addiction-specific counseling skills. So, what is the moral to the story, if one exists? Where do we focus workforce development energy with mixed messages like these? It would be interesting to hear from readers who fall on either side (or both sides) of this issue...

Monday, October 14, 2013

Advice for Mental Health Clinicians

A clinician recently sent me this email:


Dr. Willenbring,

I read an article in the New York Times from early this year discussing Effective Addiction Treatment that in part highlighted your comments and Alltyr's mission to be a 21st century model for addictions treatment.

As a therapist in an outpatient practice not specializing in addictions treatment--but who nevertheless encounters co-morbidity with substance abuse on a pretty regular basis--it can be confusing to know how to approach the psychosocial aspects of treatment. I believe in a multimodal approach for chronic forms of addiction but there are tons of options out there for my part in that process:  motivational enhancement therapy, cognitive-behavioral, contingency management interventions/motivational incentives, the matrix model, 12-step, DBT, family behavior therapy, interpersonal neurobiology, etc. There is so much out there it's dizzying, and I feel overwhelmed. There are some that seem more indicated for alcohol, others that seem better for stimulants, another for opioids. I've worked for agencies that are sold on one particular treatment for every type of substance abuser, and others that turn their therapists loose to use whatever they think best.

I want to use the best, empirically validated approaches and everyone seems to have an opinion on what that is. Where would you recommend I start, particularly for treatment options?

Here's my reply:

Hi Jxxxx,

It is indeed a confusing landscape out there, both for non-specialist clinicians and for patients and families. 

A good place to start is with the ASAM textbook on treatment of addictive disorders. It's coming out with a new edition (or it has just come out). Also, the American Psychiatric Association textbook is pretty good as an overall summary of evidence-based practice.

On an individual clinician level though it can be confusing. Here are some thoughts:

First, there is no ONE RIGHT WAY to overcome addictions. There are many different pathways. Our job is to help each person find his or her own best way.

Second, a skilled clinician is usually effective no matter the specific technique, as long as the clinician is focused on the patient, not the technique or path. Focus on general skills, such as empathy, reflective listening, unconditional positive regard, and instilling hope. There is no evidence that a specific technique is more effective than another, except in specific circumstances. The relationship is more important.

Third, be patient oriented. Take them where they are. Find out what they want, help them clarify their goals and how to reach them. Help them learn skills to achieve their goals, while also gently helping them realize that the ideal goal (use without consequences) is out of reach.

Finally, be patient and let them teach you about their disorder and its nature. Recovery is a two-steps-forward, one-step backward process. Trying and failing is a necessary step for most people, and the important thing is to accept that, learn from each step back, and then look forward. Persistence is the key. 

A couple of other things.
Never use the words denial, codependency, or enabling. Don't threaten, cajole or berate. Don't share your own experience unless it is (very) clearly in the best interests of the patient (it usually isn't). 

Never question their motivation to get better. I've never met an addict who liked being addicted. They all want to feel better, but sometimes it takes awhile to figure what the way forward is. 

Accept that you can't help everyone. Why should we be able to universally help everyone with a complex human affliction? Be humble, but hopeful and available. Never blame the patient/client for the failure of our treatments, which are modestly effective at best. People die of this disease, and too often we can't stop it or know how to help them. People die from all sorts of illnesses. It's no different to die of a dysregulation in our brain than in our heart, immune system or pancreas. We need to get over ourselves a little bit. We don't need to blame the person with the disease in order to protect ourselves from our inability to stop it. 

And keep working, and trying, and stay hopeful and alive and open hearted. That does the most of all.

Thanks for writing,

MW

Friday, April 19, 2013

I Challenge You to Find a Better Deal in Integrated Addiction & Psychiatric Treatment

First, my apologies for the drought in blogs lately. The last few weeks have been among the busiest in my life. Feels like internship all over again! Ian McLoone has been helping me with blog writing, and I haven't even had time to quickly look them over before publishing.

Busy is good to an extent, of course. The good news is that Alltyr is catching on, with very little marketing. Granted, being mentioned (with a very appreciated link) in Jane Brody's column, and the publication of Inside Rehab have propelled things along rather quickly, and to some extent it caught us off guard. But the new office in the 1st National Bank Bldg in St. Paul, MN is great. I love the building! Built in 1931, with lots of wonderful marble, and marvelous metalwork around the elevators. And, get this, planters with orchids all over the main level. In St. Paul, "the main level" is confusing. If you drive through downtown St. Paul, it looks like a kind of abandoned city on the street level. There's not much there except bus stops and the new light rail stops. Thing is, all the action occurs one story up, on the Skyway Level. Most buildings in downtown St. Paul and Minneapolis are connected to skyways. Skyways are connections between buildings 1 floor up from the street. So when I go to work there, I park in the heated garage in the building, leave my coat in the car, take the elevator to the skyway level. Here is where there are restaurants and delis, dry cleaning places, hair stylists, food courts, etc.

In addition to the office space, there are great amenities, including conference and training facilities at no extra charge and a modern workout facility, all included in the rent. And, we are in front of one of the new light rail stops, so it will be very easy to get here.

There are several suites on our current floor, which we are looking at for clinic expansion. My goal is to open a full -service SUD clinic in the fall of 2013. We are also talking to providers of sober housing. The idea is to create a comprehensive, state-of-the-art system of care that is based on 21st Century science, compassion and common sense.

We are also in discussions with local health plans, who are very interested in what we are doing. Remember, they are paying a lot for repeated useless residential and IOP rehabs. For example, a local nationally known provider charges about $30,000 for a 28-day residential rehab. I don't know what kind of discount the health plans get, but let's say they are paying $20,000 for it. Another prominent provider in the area charges $10,000 cash up front for a very pedestrian IOP with no housing. Alltyr's intensive services package, which includes a comprehensive evaluation by a physician (not a counselor), 10 1-hour psychotherapy and medication management visits, plus 25 30-minute therapy and medication visits over the course of a year, is only $4800, discounted from $5400 if purchased separately. Sober housing I'm going to estimate high at $1200 per month. So, for under $7,000, Alltyr Clinic will provide treatment services for a year plus 1 month supervised sober housing.  And with results that are guaranteed to be superior, because Alltyr's program includes completely integrated psychiatric treatment and uses all available treatment modalities.

I challenge you to find a better deal anywhere.

Thursday, February 7, 2013

The Need for Something New in Addiction Treatment

It will come as no surprise to regular readers of this blog that there is a need for new approaches to treating addictions. In particular, people with substance use disorders (SUDs) and their families need access to current, scientifically based practice and greater consumer choice of treatment modalities. Today, I've been receiving a resounding validation of this fact from the response to Jane Brody's column for the New York Times three days ago. In the last two days, I've received almost 30 calls from all parts of the US from people who are interested, if not desperate, for something new, either for themselves or for a relative who is suffering from this disease. One person called me from China!

The main focus of Jane's column was a terrific new book by Anne Fletcher titled Inside Rehab. It's already #1 on the Amazon best-seller list for alcoholism recovery books, and it's been receiving widespread coverage that is overwhelmingly positive. And this is before it's actually available to the public! (Full disclosure: I was one of many experts in the field whom Anne used as resources for her book, and since she also lives in MN, we have become friends.) Jane, with whom I had previously talked with when I was at NIH, called to talk about the book and the state of the treatment field today, and this conversation figured fairly prominently in the column.

Of course, I'm grateful for the coverage of my efforts to change the treatment system and of Alltyr, but I'm saddened by the similarity of the stories I hear time and again. Mostly, it's about going through rehab over and over, almost all of them 12-step oriented, cookie-cutter programs that show films, give lectures, send clients to 12-step groups and use low-quality group  counseling. Clients of these programs are told that the program always works if they accept it, that they must not be motivated or willing, or that they are in denial, and so forth. Families often report nearly bankrupting themselves paying for expensive residential rehab programs that don't work. In too many cases, 12-step abstinence based treatment is used for opioid addiction even though all the evidence shows it doesn't work. Almost always, these are stories about repeated episodes of time-limited low quality treatment without continuity over time, attention to co-existing psychiatric and medical disorders, or meaningful family involvement. There is very little consumer choice or even information about the various options that have been shown to work. Little has changed from when I was at NIH, and frequently gave talks and interviews that were covered in the media. I would always receive calls and emails there asking how to find evidence-based treatment.

At the same time, I am heartened by this latest demonstration of how pressing the need is, how many people are desperately wanting something new. And it inspires me anew to keep pressing forward on a mission that at times feels overwhelming, where there are so many barriers and where progress is often difficult to see. The palpable pain and suffering I hear remind me why I'm doing this. And I know I am not alone, and as more people join the effort the momentum will continue to build.

MW

Tuesday, February 5, 2013

Why SBIRT Is Dead in the Water

In the latest issue of Health Affairs, Grace Lin et al. describe an effort to introduce decision-making aids to facilitate shared decision-making regarding back pain and colo-rectal cancer screening. Essentially, nothing changed, in spite of making the aids easily accessible, conducting training sessions, and so on. What's important is the authors' conclusion that "The results of focus groups, ethnographic field notes, and surveys suggest that major structural and cultural changes in health care practice and policy are necessary to achieve the levels of use of decision aids and shared decision making in routine practice envisioned in current policy."

Their experience mirrors my own in trying for over 20 years to get substance use addressed in primary care. Most recently, I have two separate but relate experiences here in Minnesota where I essentially ran up against a brick wall. Why? First, primary care doctors are besieged by quality improvement initiatives aimed at reducing variability of practice and improving outcomes for depression, diabetes, heart failure, back pain, asthma, hypertension and many others. These are typically mandated from the top of health care organizations (remember that most primary care physicians are now employees of a large health care organization (HCO.) By attempting to implement not only SBIRT but treatment of alcohol dependence in primary care (I call it Screening, Evaluation and Treatment, or SET, but another term could be SBIRT+) by asking physicians to voluntarily take it on was a non-starter. Typical comments were "It's a good idea but we can't take on anything more right now," or "We're having enough trouble trying to get this clinic's operations running smoothly, and until we do, it wouldn't work." 


A second factor is one of priorities. I have argued for years that universal SBIRT is not cost-effective, but should be more targeted. Related to this is a crucial question: since visit length is not going to increase, what do you want the doctor to stop doing so they can do these new things, like shared decision-making and SBIRT+?  In other words, in a typical visit, the patient has certain expectations about why they are there and what they want, and most patients have multiple chronic diseases like obesity, arthritis, hypertension and diabetes. Oh, and of course they smoke. So, do you want the doctor to not address the patient's presenting complaint (e.g., arthritis pain, insomnia), or not address their hypertensive control so they have the time to spend on shared decision-making for back pain, or to conduct SBIRT+? How do you think patients would feel about this? This applies especially to SBIRT, because it is attempting to identify a problem they patient is unaware of and not concerned about. "Doctor, I came here because my right knee is all swollen and painful, and you want to take 2 out of the 8 minutes you spend with me asking me about drinking!?"

So have come to a similar conclusion: until the medical home concept is fully implemented, with team care that includes a focus on health behaviors of all types, SBIRT or SET are DOA. My most recent attempt has been to start with something that has the attention of every primary care doctor: pain management. I'm providing training to all the primary care doctors in Allina Health in management of chronic pain, and the response so far has been overwhelmingly positive. I'm hoping that by getting to know so many primary care physicians in this HCO, they will be more receptive to introducing SET. However, it has also become clear that the only way this will occur is if the top leadership of the organization decides that SET is important enough to get it into the queue of quality improvement projects, and thus mandate its implementation. 

Primary care, even with the medical home, is not going to be all things to all people, and choices are going to have to be made about what is important enough to include and what might ideally be included but which doesn't make the cut because it is not cost-effective or clinically significant enough.

Besides, if we were serious about addressing the heavy disease burden associated with heavy drinking, we would triple the taxes on alcoholic beverages. That would have a greater public health impact than implementing SBIRT in every primary care practice in the country. 

MW

Here's the abstract:


An Effort To Spread Decision Aids In Five California Primary Care Practices Yielded Low Distribution, Highlighting Hurdles

  1. Dominick L. Frosch7,*
+Author Affiliations
  1. 1Grace A. Lin is an assistant professor in the Division of General Internal Medicine and at the Philip R. Lee Institute for Health Policy Studies at the University of California, San Francisco.
  2. 2Meghan Halley is an assistant research anthropologist in the Department of Health Services Research at the Palo Alto Medical Foundation Research Institute, in California.
  3. 3Katharine A.S. Rendle is a research associate in the Department of Health Services Research at the Palo Alto Medical Foundation Research Institute.
  4. 4Caroline Tietbohl is a research assistant in the Department of Health Services Research at the Palo Alto Medical Foundation Research Institute.
  5. 5Suepattra G. May is an assistant research anthropologist in the Department of Health Services Research at the Palo Alto Medical Foundation Research Institute.
  6. 6Laurel Trujillo is medical director of quality at the Palo Alto Foundation Medical Group and chair of the Quality Improvement Steering Committee, both at the Palo Alto Medical Foundation, in Los Altos, California.
  7. 7Dominick L. Frosch (dominick.frosch@moore.org) is an associate adjunct professor in the Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California, Los Angeles.
  1. ↵*Corresponding author

Abstract

Despite the proven efficacy of decision aids as interventions for increasing patient engagement and facilitating shared decision making, they are not used routinely in clinical care. Findings from a project designed to achieve such integration, conducted at five primary care practices in 2010–12, document low rates of distribution of decision aids to eligible patients due for colorectal cancer screening (9.3 percent) and experiencing back pain (10.7 percent). There were also no lasting increases in distribution rates in response to training sessions and other promotional activities for physicians and clinic staff. The results of focus groups, ethnographic field notes, and surveys suggest that major structural and cultural changes in health care practice and policy are necessary to achieve the levels of use of decision aids and shared decision making in routine practice envisioned in current policy. Among these changes are ongoing incentives for use, physician training, and a team-based practice model in which all care team members bear formal responsibility for the use of decision aids in routine primary care.

Tuesday, November 6, 2012

Hazelden Starts Suboxone Maintenance!

Many of you may already have heard that Hazelden is starting a pilot project involving Suboxone maintenance treatment. This landmark shift is primarily due to the skill and persistent effort of Marv Seppala, MD, Hazelden's Chief Medical Officer. Marv and I go way back. I was on the faculty in the Department of Psychiatry at the University of Minnesota when Marv was a resident and then, subsequently, an addiction psychiatry fellow. He and I have stayed in touch ever since, and he and I and Carol Falkowski, another member of the old guard in Minnesota get together for lunch every few months. Marv is a great guy in addition to being a top-notch physician and psychiatrist. He is one of the few people who could make something like this happen. He is widely respected in the 12-Step and addiction treatment worlds, yet he is also a true professional who reads the research and believes in science. When he returned here to Minnesota from Oregon (where his true home still is) to work at Hazelden the second time (he was Chief Medical Officer for a period of time, then left due to disagreements with the then-CEO of Hazelden, then came back to work under a new CEO) we had dinner one night. I argued that not providing Suboxone and/or methadone maintenance treatment to opioid addicts was negligent given how strong the support was in the literature, and at that time, he said that their outcomes for opioid addicts was similar to those of other patients. More recently, as we discussed this new initiative, he told me that one of the primary forces driving the Board to adopt this shift was the number of poor outcomes from strictly abstinence-based 12-Step treatment. (No news to me, some of my Suboxone patients have completed multiple 12-step treatments including at Hazelden.)

Hazelden's new approach is a seismic shift that is likely to move the entire industry in this direction. I told Marv that it was like the Vatican opening a family planning clinic! However, although this is a major positive step, they continue to be wedded to a strictly 12-Step approach along with the medication. I don't see this ever changing. Hazelden has always seemed to operate like a Catholic hospital: science was ok as long as it didn't conflict with ideology, and when it did, ideology won out. It is still pretty much like that I think, but to their credit they have been prescribing anti-relapse medications for alcohol dependence for some time. To those rabid, fundamentalist 12-Steppers who consider anti-relapse medications a "crutch" (in a negative way), my reply is that when you break your ankle, a crutch facilitates healing, and anti-relapse medications do so as well. Rather than "weaken" recovery, they can help some people achieve long-term recovery who would otherwise fall by the wayside. It will be interesting to see how this all plays out in the 12-Step community. My patients tell me that in Narcotics Anonymous there has been increasing acceptance of Suboxone in particular, in contrast to methadone maintenance, which is still regarded as "using" by many because you can still get high while taking it.

MW

Monday, October 29, 2012

Can We Trust Scientific Research?


A comment from a Twitter follower (@AddictionDrW) asserted that studies supporting the effectiveness of opioid maintenance therapy for opioid addiction must have been funded or supported in some way by "Big Pharma" and therefore cannot be trusted. He rejected all the research, saying that we should be listening to recovering addicts instead, or that "evidence is mixed." Is that true?

Methadone was invented in Germany as an analgesic during WWII. The first study of methadone maintenance, by Vincent Dole, Marie Nisswander and then-resident Mary Jeanne Kreek, was funded not by Big Pharma (who wanted nothing to do with "junkies"), but by the Health Research Council of New York City, due to the failure of abstinence-based approaches in the face of a growing heroin problem (Joseph et al., 2000). To my knowledge, it's never been a significant money maker for a large pharmaceutical company. Subsequent studies have for the most part been funded by government organizations such as the National Institutes on Health (NIH). The most recent large study of Suboxone maintenance for prescription opioid addicts, was funded by the NIH.

If NIH funded research, conducting in a rigorous way, is not trustworthy information, then what is? In my mind this is a way of asserting, in essence, that whatever one wants to believe is true. There are no objective methods to determine whether one assertion is true and its opposite is false. Therefore, there can be no accumulated knowledge, and we are all on our own, depending on whatever we wish to believe, or have heard from others. We can simply reject information we don't like or agree with and accept evidence that supports what we believe.


I don't think that is a supportable position, because it leads to the radical conclusion that there is no objective truth, only subjective opinions. Please, folks, how besides through scientific research are we going to improve outcomes for addiction treatment? And if we choose only to believe results that support our pre-existing ideas, how can we progress?


I understand that we all operate that way to a significant degree, because these biases are built into our brain structure and function, and are almost completely unconscious  Why is not clear, but then traits that nature selects through evolution seldom have immediately clear rationales. As my colleague, Steve Gilbert, argued in a previous blog, we make decisions and then rationalize them after the fact. We weave a coherent narrative of our lives because we need to. We need reasons why things happen, we need to feel in control, and we need to feel like a specific person with a specific history and characteristics. We need be able to explain how we arrived at a decision, and to simply say, "My gut told me so," is seldom adequate. Imagine a presidential debate where that was the rationale for political positions: "It just feels right to me."

On the other hand, it is because of these biases that the scientific method was devised: to minimize bias, to constrain interpretation, and to reveal the precise basis for arriving at a specific conclusion, so that others could replicate the study. Although single large trials may be provide evidence so strong that it changes thinking and practice, more often it is an accumulation of evidence from many studies conducted by multiple independent scientists. Evidence from multiple studies is then collected into systematic reviews, and if there are enough high-quality studies, are then subjected to an obscure procedure called meta-analysis. Meta-analysis is a systematic statistical method for combining findings across studies in order to determine whether, overall, a particular treatment is more effective than its alternative. Two famous examples are aspirin and beta-blockers for prevention of heart attacks after a first heart attacks. It wasn't until the meta-analyses were done that it became clear that these are effective approaches. Sometimes, it takes multiple meta-analyses before a conclusion can really be drawn.

Recent history is littered with examples of approaches that were fervently held and promoted prematurely. How many thousands of women underwent a horrendous and often fatal procedure, bone-marrow transplant, to treat end-stage breast cancer, before it was shown to be ineffective? At the time, women were lobbying legislatures around the country to mandate insurance coverage for it. Those of us who said, "Wait for the research before moving ahead," were shouted down, with tragic consequences for the unfortunate women who received the procedure and their families. Hormone replacement after menopause is another example, being strongly recommended and widely prescribed in the past, to prevent osteoporosis and heart disease, only to learn through meta-analyses, as well as very large well-done trials, that the treatment is actually harmful.

Perhaps the best recent example is that of PSA testing for prostate cancer in men. It was never clear that PSA testing was a good idea, but it became extremely widespread, if not universal. Millions of men have had  prostate biopsies (a very unpleasant procedure,) radical prostatectomies, radiation that scarred their rectums, and other treatments that left them incontinent and impotent. However, two large randomized controlled trials, one in the US and one in Europe, determined that almost all the tumors being treated were slow-growing and probably would never require treatment if left alone. In one trial, there was no difference in mortality, while in the other, there was a slight advantage to PSA testing, but 50 men would have to be treated in order to save one life. I know I don't want to be one of the 49 treated who didn't need it.

However, PSA testing is still popular in the US. Why? Because we are terrified of cancer, and we have been told that "catching it early and getting it out" is the best way to avoid dying of it. Many urologists refuse to believe the studies, based I would guess on their experience treating men with advanced, fast-growing tumors. (It's not even clear that treating fast-growing tumors alters survival.) I don't believe this is because of their financial interests in performing procedures; I know physicians too well to believe they don't have their patients' best interests in their minds and hearts. But they suffer from biases as well. We whack out prostates not because it is beneficial to most men undergoing surgery, we do it because it "feels like the right thing to do."

One of the reasons our health care costs so much is because of our refusal to stop funding ineffective or harmful medical procedures and treatments because "people want them." Here's another example: people presenting to the doctor with back pain were randomly (like the toss of a coin) assigned to either 1) receive regular XRays of their spine, or 2) to get an MRI. After one year, what was the result? In terms of function and pain, there were no significant differences. But there was one significant difference: people getting an MRI had more surgery. The fact is, most people over the age of 35 have abnormal MRIs of their spines, but the correlation with clinical symptoms is very low. And yet, people traipse into the doctor's office demanding an MRI of their back "because I want to know what it is." And the US does more back surgery than any other country in the world, probably more than the rest of the world combined, with highly dubious results. We also consume more prescription opioid pain medication than the rest of the world combined. So biases of this type are not limited to the field of addiction treatment. However, there is one difference: urologists and other physicians are obligated to advise patients of all alternative treatments and to do so in an unbiased way. The patient needs this information to make an informed decision.

A footnote about the "the evidence is mixed" strategy. This approach is not new, having been used by tobacco company executives and climate change deniers for many years. It is always possible to find one of 6 scientists in the world who reject climate change, and then present their opinions as equivalent to the 95% of scientists who are convinced of the evidence. This is a problem with current media, an obsession with presenting two sides to the story without providing the context of the overwhelming majority opinion or of the research itself. In the case of opioid maintenance treatment, the evidence is simply overwhelming in showing that it reduces relapse to addictive use, improves health and function, and reduces crime, and that abstinent-based approaches do not. If you choose to believe something else, that's up to you, but a professional in my opinion has en ethical responsiblity to accept scientific findings and act accordingly. In similar vein, anti-relapse medications for smoking and for alcohol use disorder are not home runs, but they improve outcomes consistently. To say otherwise is to filter the evidence according to preference, to see only what one wants to see. Treatment programs and their professional staff members who deny people with a devastating and often fatal illness access to these treatments, or even to information about them, are imposing their own biases and beliefs on their clients, in violation of the basic tenets of informed consent.

References
Joseph H, Stancliff S, Langrod J. (2000) Mt Sinai J Med 67:347.






Friday, October 19, 2012

Informed Consent: The Best Way to Promote Evidence-based Practice?

Yesterday, I was one of three experts participating in a new Huffington Post initiative called HuffPost Live. This one was on medications for SUDs, and it can be viewed here. What caught the attention of the producer of HuffPost Live was the Salon.com article, which was picked up from TheFix.com (thanks again to Sacha Scoblic, the author of the article.) 

It was an interesting interchange. I got pretty incensed when one of the "experts," Justin Hewitt, who runs a sober living facility in Los Angeles, said that the evidence about the effectiveness of maintenance treatment for opioid addiction was mixed, that there was evidence on both sides. I don't think I handled it especially well from a communications standpoint, since the moderator then ignored me and went on to ask about his personal "story" about recovery from addiction. I also re-learned that talking about studies seems to put people to sleep, but anecdotes carry real power (see: election, Presidential.) I think I redeemed myself at the end, adopting a more measured tone, and I was able to get the point across that most people with addiction eventually get well, a positive note that the moderater ended the program with.

But I no longer have any patience with treatment professionals who ignore the overwhelming evidence that abstinence based approaches simply do not work for most people with opioid addiction, or worse, distort the evidence. People are dying because of this every day. We lament the fact that deaths from opioid overdoses are up, and then we fail to provide easy and cheap access to live-saving treatment with Suboxone or methadone. Patients and families (and insurance companies, that is, us) spend hundreds of thousands of dollars repeatedly going through 12-step rehab, only to relapse within weeks or months after program completion. And people are dying because of this. In one study in the UK, the death rate among people discharged from methadone programs shot up as high as 8 fold in the following months. 

The program also reinforced an evolving belief of mine, that the best way to advance evidence-based treatment of addiction is to focus on the professional duty to provide full informed consent, something lacking in most treatment facilities. Addiction treatment providers are not held to the same ethical standards of other health care professionals. Justice Cordozo, in a frequently cited landmark court case, Schloendorff v. Society of New York Hospital (1914), stated that "Every human being of adult years and sound mind has the right to determine what shall be done with his own body..." Using that principle as a basis, the current obligation for providing informed consent was established by the D.C. Court of Appeals in another landmark case, Canterbury v Spence (1972). Prior to Canterbury v Spence, the standard had been physician-oriented, based on what the local standard of practice was for informing patients. This led to the common practice of failing to disclose a diagnosis of cancer to a patient, while often informing a spouse, because the physician decided it was in the patient's best interests not to know. In Canterbury v Spence, the court established the principle that a physician's obligation was to give the patient information about a proposed medical treatment, based on what a reasonable person would want to know, in order to make a fully informed decision. They also found that the "the patient's right of self-decision shapes the boundaries of the duty to reveal." Subsequent rulings in other jurisdictions have refined this to find that failure to inform the patient about risks, benefits and alternative treatments violated ethics and law even if the treatment provided was not done negligently. That is, providing competent treatment that the patient may have rejected had they been fully informed was also wrong and potential cause of action. 

So, if someone is seeking treatment for addiction, and meets a professional like Mr. Hewitt, she will be be getting a distorted and factually incorrect account of what the evidence shows, and what the relative risks and benefits of different treatments are. She will typically be told that whatever the treatment the facility provides is the most effective treatment available, and often will be instructed to discontinue more effective treatments, especially medication. That is not the basis for an informed decision, and in my view, this lack of informed consent is unethical, negligent and inexcusable. 

State agencies and the federal government are complicit in keeping the truth from the public. Out of misplaced fear of offending programs, staff and many recovering people who "do not believe in" certain evidence-based treatments, state licensing agencies allow addiction programs to offer virtually anything without regard for its basis. Some programs provide "nutritional therapy," others treat addiction with religion (not spirituality as is the case in 12-Step treatment programs, but actual specific religious practices,) while others use "equine therapy," "golf therapy," hypnosis and acupuncture. I would bet that fewer than 10% of programs or addiction therapists provide true informed consent. The Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Drug Abuse (NIDA) soft-pedal their recommendations, which are supposed to be evidence-based, for the same reason. For example, their publications often say things like "Medications may also become an essential component of an ongoing treatment plan, enabling opioid-addicted persons to regain control of their health and their lives." (NIDA Topics in Brief: Medication-Assisted Treatment for Opioid Addiction, 2012; emphasis mine.) Even the term "Medication-Assisted Treatment" is designed so as not to offend the ideologues who hate the idea that "working the program" might not be enough. The term suggests that the primary treatment is counseling, but in the treatment of opioid addiction, counseling is adjunctive to the primary treatment. We don't call using insulin for diabetes medication-assisted treatment, even though counseling and behavior change are as essential to proper diabetes management as they are in addiction treatment. A correct statement is this: "The only treatment proven effective for treating established opioid addiction is maintenance on a medication such as Suboxone or methadone, often with adjunctive counseling. Studies show that maintenance treatment reduces illness, mortality and crime, and is highly cost-effective. Therefore, it is the first-line treatment and the treatment of choice. There is no evidence of effectiveness for abstinence-based treatment." 

Adults who are fully informed can make whatever decision they wish. If they want to go to a shaman, homeopath, naturopath, chiropractor, herbalist, spiritual healer or Reiki master for treatment of a medical condition, that's their business. But people who are deprived of access to unbiased information concerning the effectiveness, risk, benefits, and alternatives to treatments provided by a licensed professional or treatment program cannot make an informed decision. I'm waiting for the wrongful death lawsuit by a family whose loved-one died because he was not informed of the effectiveness of maintenance treatment of opioid addiction. The program will lose in court. Unfortunately, that may be what it takes to change the behavior of the addiction treatment industry.